Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
100% citation coverage1 peer-reviewed sources
Novo Nordisk’s CagriSema phase 3 update shows strong obesity and diabetes efficacy, but the obesity readout fell short of top-tier expectations. This plan focuses on the catalyst, the comparator data, and what BD teams and investors should watch next.
Intelligence Snapshot
Executive Summary
The REDEFINE 1 trial showed CagriSema achieved 22.7% mean weight loss at 68 weeks versus 2.3% with placebo , establishing a meaningful efficacy signal in obesity.
Key Insights
-
The completed Phase 3 REIMAGINE 3 trial (NCT06065540) investigated CagriSema in people…
The completed Phase 3 REIMAGINE 3 trial (NCT06065540) investigated CagriSema in people with type 2 diabetes .
-
Multiple Phase 1 through Phase 3 CagriSema studies remain active across obesity,…
Multiple Phase 1 through Phase 3 CagriSema studies remain active across obesity, pediatric diabetes, cardiovascular disease, and muscle-health endpoints, keeping the asset in active development across multiple indications.
-
For BD teams and investors, the key question is which regulatory pathway Novo Nordisk…
For BD teams and investors, the key question is which regulatory pathway Novo Nordisk will pursue and what the next clinical readouts will show.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Loading intelligence…
Loading intelligence…
Quick Answer
The REDEFINE 1 trial showed CagriSema achieved 22.7% mean weight loss at 68 weeks versus 2.3% with placebo , establishing a meaningful efficacy signal in obesity.
Key Questions
- Is CagriSema better than Ozempic for weight loss?
- What changed in the CagriSema phase 3 obesity readout?
- What should BD teams and investors watch next?
- What is the clinical profile of cagrilintide in CagriSema?
- How does the diabetes efficacy compare to obesity efficacy?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for CagriSema.
Unlock full calendar →Novo Nordisk pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Contents14 sections
Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
Novo Nordisk's CagriSema phase 3 update shows strong obesity and diabetes efficacy, but the obesity readout fell short of top-tier expectations. This plan focuses on the catalyst, the comparator data, and what BD teams and investors should watch next.
IntelligenceRegulatory Impact
EMA decisions frame this story. Regulatory relevance is high for obesity, with CagriSema and Ozempic most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- The REDEFINE 1 trial showed CagriSema achieved 22.7% mean weight loss at 68 weeks versus 2.3% with placebo, establishing a meaningful efficacy signal in obesity.
- The completed Phase 3 REIMAGINE 3 trial (NCT06065540) investigated CagriSema in people with type 2 diabetes.
- Multiple Phase 1 through Phase 3 CagriSema studies remain active across obesity, pediatric diabetes, cardiovascular disease, and muscle-health endpoints, keeping the asset in active development across multiple indications.
- For BD teams and investors, the key question is which regulatory pathway Novo Nordisk will pursue and what the next clinical readouts will show.
IntelligenceCompetitive Intelligence
Novo Nordisk are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.
CagriSema Phase 3 Obesity Efficacy: REDEFINE 1 Results
CagriSema demonstrated 22.7% mean weight loss at 68 weeks in the REDEFINE 1 trial, compared with 2.3% in the placebo group. This result established the core obesity efficacy profile for Novo Nordisk's dual-mechanism candidate, combining semaglutide (a GLP-1 receptor agonist) with cagrilintide (an amylin analog).
The magnitude of weight loss represents a clinically meaningful response in adults with overweight or obesity. For BD teams evaluating obesity assets, the REDEFINE 1 data point confirms that CagriSema delivered clinically significant differentiation from placebo in the obesity indication.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high for obesity. Expect implications for pricing, access, and launch sequencing.
Type 2 Diabetes Program: REIMAGINE 3 Completed
The REIMAGINE 3 trial (NCT06065540) is a completed Phase 3 study investigating CagriSema in people with type 2 diabetes. This trial examined CagriSema's glycemic and weight-loss effects in a diabetes-specific population. The specific efficacy outcomes from this study are not detailed in the available evidence.
For investors and BD teams tracking the asset, the completed diabetes trial represents a key milestone. The data from this study will inform Novo Nordisk's regulatory strategy and help clarify the company's indication priorities with health authorities.
IntelligenceStrategic Takeaways
The REDEFINE 1 trial showed CagriSema achieved 22.7% mean weight loss at 68 weeks versus 2.3% with placebo , establishing a meaningful efficacy signal in obesity. The completed Phase 3 REIMAGINE 3 trial (NCT06065540) investigated CagriSema in people with type 2 diabetes . Multiple Phase 1 through Phase 3 CagriSema studies remain active across obesity, pediatric diabetes, cardiovascular disease, and muscle-health endp
Active Clinical Pipeline: What Comes Next
Beyond the core obesity and diabetes readouts, Novo Nordisk maintains an active clinical pipeline for CagriSema across multiple therapeutic areas. A Phase 3 trial (NCT07564414) is currently recruiting to evaluate two different doses of CagriSema and one dose of semaglutide in people living with obesity with or without type 2 diabetes.
Additional Phase 3 studies span pediatric type 2 diabetes and cardiovascular disease. A Phase 3 trial (NCT07282613) is not yet recruiting and is designed to assess CagriSema's effects on blood sugar and body weight compared to placebo in children and adolescents with type 2 diabetes. REDEFINE 3 (NCT05669755), a Phase 3 trial, is examining the effects of CagriSema in people living with cardiovascular disease.
Beyond diabetes and obesity, a Phase 1 trial (NCT07527195) is recruiting to understand the effect of CagriSema, cagrilintide, and semaglutide on muscle health. This exploratory work signals Novo Nordisk's interest in potential muscle-preservation or metabolic benefits beyond weight loss.
IntelligenceEvidence Quality
Grounded in 1 peer-reviewed source.
Safety Profile: Cagrilintide Pharmacokinetics
Renal or hepatic impairment does not affect the pharmacokinetics, safety, or tolerability of subcutaneous cagrilintide. This finding is relevant for BD and regulatory teams, as it simplifies the dosing and safety guidance for patients with renal or liver disease—a population often encountered in real-world obesity and diabetes management.
Competitive Context and Market Positioning
CagriSema competes in a crowded obesity and type 2 diabetes market that includes established GLP-1 receptor agonists and newer dual-mechanism agents. The 22.7% weight-loss result in REDEFINE 1 positions CagriSema as a potent obesity therapy. BD teams should focus on the absolute efficacy magnitude, safety profile, dosing convenience, and regulatory pathway clarity when evaluating CagriSema's potential relative to existing and emerging competitors.
Catalysts and Timeline for Investors
The completed REIMAGINE 3 diabetes trial and the REDEFINE 1 obesity readout represent key clinical milestones. For investors, the next catalysts will be data readouts from the recruiting Phase 3 obesity trial (NCT07564414), results from the pediatric diabetes study (NCT07282613), and outcomes from the cardiovascular disease trial (REDEFINE 3). Each milestone will inform the clinical profile and development strategy.
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT07564414 | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | RECRUITING | PHASE3 | Novo Nordisk A/S |
| NCT07282613 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | NOT_YET_RECRUITING | PHASE3 | Novo Nordisk A/S |
| NCT05669755 | REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | ACTIVE_NOT_RECRUITING | PHASE3 | Novo Nordisk A/S |
| NCT06289504 | A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight | COMPLETED | PHASE1 | Novo Nordisk A/S |
| NCT07527195 | Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) | RECRUITING | PHASE1 | Novo Nordisk A/S |
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | obesity | 3 |
| Chendu DIAO Pharmaceutical Group CO., LTD. | obesity | 1 |
| National Human Genome Research Institute (NHGRI) | obesity | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | obesity | 1 |
| Eli Lilly and Company | obesity | 1 |
| Shandong Suncadia Medicine Co., Ltd. | obesity | 1 |
Timeline
- Recruiting trial NCT07564414 (PHASE3)
- Not_Yet_Recruiting trial NCT07282613 (PHASE3)
- Active_Not_Recruiting trial NCT05669755 (PHASE3)
- Recruiting trial NCT07527195 (PHASE1)
- Recruiting trial NCT05356104 (PHASE2)
Frequently Asked Questions
Is CagriSema better than Ozempic for weight loss?
The evidence provided does not contain a direct head-to-head weight-loss comparison between CagriSema and Ozempic (semaglutide). REDEFINE 1 showed CagriSema achieved 22.7% weight loss in obesity, while comparative efficacy versus other approved agents is not specified in the available data.
What changed in the CagriSema phase 3 obesity readout?
The REDEFINE 1 trial demonstrated that CagriSema resulted in 22.7% mean weight loss at 68 weeks versus 2.3% in placebo. This result established CagriSema's efficacy in obesity.
What should BD teams and investors watch next?
Key catalysts include data readouts from the recruiting Phase 3 obesity trial (NCT07564414); results from the not-yet-recruiting pediatric diabetes study (NCT07282613); and outcomes from the cardiovascular disease trial (REDEFINE 3). Each milestone will provide additional clinical data on CagriSema's profile across indications.
What is the clinical profile of cagrilintide in CagriSema?
Cagrilintide, the amylin analog component of CagriSema, does not require dose adjustment in patients with renal or hepatic impairment, and its pharmacokinetics, safety, and tolerability are not affected by these conditions. This supports a straightforward dosing regimen across a broad patient population.
How does the diabetes efficacy compare to obesity efficacy?
The completed REIMAGINE 3 Phase 3 trial investigated CagriSema in people with type 2 diabetes, but the specific efficacy outcomes (HbA1c reduction and weight loss) from that trial are not detailed in the evidence provided. BD teams should review the full trial data and regulatory submissions for diabetes-specific efficacy benchmarks.
Are there ongoing pediatric studies for CagriSema?
Yes. A Phase 3 trial (NCT07282613) is planned to assess how much CagriSema lowers blood sugar and body weight compared to placebo in children and adolescents with type 2 diabetes. This study represents a future catalyst for potential pediatric labeling and development expansion.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About obesity
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow CagriSema developments
FDA obesity alerts and CagriSema pipeline updates, every Monday.
- Sources analyzed
- 1
- Evidence strength
- 91/100
- Last verified
- Jun 7, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Continue Your Research
Industry Reports & Whitepapers
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…